Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 1 April 2006, Vol. 107, No. 7, pp. 2592-2593.

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thorley-Lawson, D. A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Thorley-Lawson, D. A.
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow


InsideBlood

NEOPLASIA

Host EBV communication

David A. Thorley-Lawson

TUFTS UNIVERSITY SCHOOL OF MEDICINE

A paper by Kis and colleagues demonstrates that B cells latently infected with EBV can modulate their transcription program in response to host-derived signals as the cells transit the germinal center (GC) into memory.

Epstein-Barr virus (EBV) is associated with important human cancers and is known to exhibit very disparate biologies. Infection of B lymphocytes in vitro invariably leads to their transformation into proliferating, activated lymphoblasts through the expression of 9 latent proteins (the growth transcription program or latency III). In contrast, the virus is quiescent in vivo, persisting in resting, peripheral memory B cells that express none of the latent proteins (the latency program). The reconciliation of these behaviors came with the understanding that EBV uses normal B-cell biology to establish and maintain persistent infection.1 Specifically, EBV uses the growth program in vivo to activate newly infected B cells so they can differentiate through a GC to become resting, latently infected memory B cells (see figure). However, the growth program does not allow differentiation, so, once activated, the latently infected cell in the GC must switch its transcription program to a more restricted form of latency (the default program or latency II) where only 3 latent proteins are expressed. The crucial players in this program are LMP1 and LMP2a, which are able to give signals necessary for the latently infected cells to enter, survive, and leave the GC. We know this is a bona fide program of the virus because it is also found in Hodgkin disease, which is believed to arise from a latently infected GC cell. What we do not know is how EBV turns on the default program. In the growth program, expression of LMP1 and LMP2a is strictly controlled by the viral transcription factor EBNA2, but EBNA2 is not expressed in the default program. Kis and colleagues now show that LMP1 expression can be turned on in the absence of EBNA2 through signals provided by the cytokine environment present in GCs. Specifically, IL-10 is able to mediate this response. This is particularly apropos because IL-10 is known to drive IgA class switching.2 This raises the possibility that the interplay between IL-10 and the latently infected cells in the GCs may extend beyond turning on the default program to ensuring a predisposition for homing to the mucosal epithelium where EBV ultimately replicates and is shed into saliva.

Crucially, the authors do not address LMP2a, the other key signaling component of the default program. Is it also turned on or is it regulated independently? There is reason to believe that LMP2A is expressed before LMP1 in vivo since LMP2a drives GC development,3 whereas LMP1 turns off bcl-6,4 a crucial step for exiting the GC. Curiously, Kis et al did not see down-regulation of bcl-6 by LMP1—a conflict that needs to be resolved.

Many questions remain unanswered about how EBV switches from growth to default to latency transcription programs in its progress from new infection to persistence in memory cells. This paper demonstrates that this progress involves an interplay between virus- and host-derived signals. {blacksquare}Go


Figure 1
View larger version (33K):
[in this window]
[in a new window]
 
This figure shows how EBV uses different transcription programs to access and persist in memory B cells and how IL-10 may play a role in regulating the process.

 
Footnotes

Comment on Kis et al, page 2928

References

  1. Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol. 2001;1: 75-82.[CrossRef][Medline] [Order article via Infotrieve]

  2. Defrance T, Vanbervliet B, Briere F, Durand I, Rousset F, Banchereau J. Interleukin 10 and transforming growth factor beta cooperate to induce anti-CD40-activated naive human B cells to secrete immunoglobulin A. J Exp Med. 1992;175: 671-682.[Abstract/Free Full Text]

  3. Casola S, Otipoby KL, Alimzhanov M, et al. B cell receptor signal strength determines B cell fate. Nat Immunol. 2004;5: 317-327.[CrossRef][Medline] [Order article via Infotrieve]

  4. Panagopoulos D, Victoratos P, Alexiou M, Kollias G, Mosialos G. Comparative analysis of signal transduction by CD40 and the Epstein-Barr virus oncoprotein LMP1 in vivo. J Virol. 2004;78: 13253-13261.[Abstract/Free Full Text]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

IL-10 can induce the expression of EBV-encoded latent membrane protein-1 (LMP-1) in the absence of EBNA-2 in B lymphocytes and in Burkitt lymphoma- and NK lymphoma-derived cell lines
Lorand L. Kis, Miki Takahara, Noemi Nagy, George Klein, and Eva Klein
Blood 2006 107: 2928-2935. [Abstract] [Full Text] [PDF]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thorley-Lawson, D. A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Thorley-Lawson, D. A.
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020